{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:30:06Z","timestamp":1761921006065,"version":"build-2065373602"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006380","name":"Rehabilitation Research and Development Service","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006380","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","award":["2RX001180"],"award-info":[{"award-number":["2RX001180"]}],"id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.msard.2022.103785","type":"journal-article","created":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T21:27:31Z","timestamp":1648589251000},"page":"103785","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3863-045X","authenticated-orcid":false,"given":"Collin","family":"Jakubecz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaochun Susan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophia","family":"Woodson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5346-8254","authenticated-orcid":false,"given":"Hesham","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2022.103785_bib0016","article-title":"Humoral immune response to COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy disease-modifying therapies","volume":"14","author":"Achiron","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.msard.2022.103785_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/s41591-021-01507-2","article-title":"Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy","author":"Apostolidis","year":"2021","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.msard.2022.103785_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mrna-1273 sars-cov-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"0","key":"10.1016\/j.msard.2022.103785_bib0014","article-title":"Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study","volume":"0","author":"Barda","year":"2021","journal-title":"The Lancet"},{"issue":"5","key":"10.1016\/j.msard.2022.103785_bib0005","doi-asserted-by":"crossref","first-page":"e1055","DOI":"10.1212\/NXI.0000000000001055","article-title":"Impact of disease-modifying treatments of multiple sclerosis on anti\u2013sars-cov-2 antibodies: an observational study","volume":"8","author":"Bigaut","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.msard.2022.103785_bib0010","article-title":"Humoral and t-cell response to sars-cov-2 vaccination in patients with multiple sclerosis treated with ocrelizumab","volume":"23","author":"Brill","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2022.103785_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103413","article-title":"B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study","volume":"57","author":"Conte","year":"2022","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.msard.2022.103785_bib0011","article-title":"Association of disease-modifying treatment and anti-cd20 infusion timing with humoral response to 2 sars-cov-2 vaccines in patients with multiple sclerosis","volume":"23","author":"Disanto","year":"2021","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.msard.2022.103785_bib0006","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1212\/CPJ.0000000000000238","article-title":"Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS: Patient management considerations","volume":"6","author":"Fox","year":"2016","journal-title":"Neurol Clin Pract"},{"key":"10.1016\/j.msard.2022.103785_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103636","article-title":"Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy","volume":"73","author":"Gadani","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.msard.2022.103785_bib0008","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102306","article-title":"COVID-19 in 7 multiple sclerosis patients in treatment with ANTI-CD20 therapies","volume":"44","author":"Meca-Lallana","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"27","key":"10.1016\/j.msard.2022.103785_bib0002","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the bnt162b2 mrna covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.msard.2022.103785_bib0003","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose ad26. Cov2. S vaccine against covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2022.103785_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103581","article-title":"CovaXiMS study group on behalf of the Italian Covid-19 Alliance in MS. Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies","volume":"72","author":"Sormani","year":"2021","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.msard.2022.103785_bib0004","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jama.2021.15125","article-title":"Comparison of sars-cov-2 antibody response following vaccination with bnt162b2 and mrna-1273","volume":"326","author":"Steensels","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.msard.2022.103785_bib0009","article-title":"COVID-19 vaccine response in people with multiple sclerosis","author":"Tallantyre","year":"2021","journal-title":"Ann. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822003005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:01:07Z","timestamp":1761901267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822003005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":16,"alternative-id":["S2211034822003005"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.103785","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.103785","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103785"}}